ACXP vs NAOV vs PRAX vs ARAY vs NVCR

For growth investors, NanoVibronix, Inc.

(NAOV) is the stronger pick with 12. 0% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). Analysts rate Praxis Precision Medicines, Inc. (PRAX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -20. 8%, compared to -99. 9% for NanoVibronix, Inc. (NAOV). Over 10 years, the gap is even starker: NVCR returned +38. 5% versus NAOV's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.

(PRAX) is the lower-risk stock at 1. 40β versus Accuray Incorporated's 2. 66β — meaning ARAY is approximately 90% more volatile than PRAX relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NanoVibronix, Inc.

(NAOV) is pulling ahead at 12. 0% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Over a 3-year CAGR, NAOV leads at 14. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Acurx Pharmaceuticals, Inc.

(ACXP) is the more profitable company, earning 0. 0% net margin versus -144. 8% for NanoVibronix, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARAY leads at 1. 7% versus -140. 0% for NAOV. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Praxis Precision Medicines, Inc.

(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Acurx Pharmaceuticals, Inc. (ACXP) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRAX: -20. 9%, ACXP: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.